Further re Final Results
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, following the publication of its audited results for the year ended 31 December 2023 on 15 May 2024 and shareholder feedback and communication, a clarification as to its cash position and recent fundraising activities.
As stated in the announcement of 15 May 2024, the cash balance of the Company as at 31 December 2023 was £174,684. Subsequent to the financial year end and as set out in the same announcement, the Company raised approximately £1.8m, before expenses, through the issue of new ordinary shares in January 2024. As at 15 May 2024, the Company's cash position was approximately £1.1m.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.